Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 39

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

New and emerging treatment of Staphylococcus aureus infections in the hospital setting

Moreillon, P.·2008·Clinical Microbiology and Infection

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1469-0691.2008.01961.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 59

  1. Styers, 2006, Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States, Ann Clin Microbiol Antimicrob, 5, 2, 10.1186/1476-0711-5-2 · DOI · Paper page
  2. Noskin, 2005, The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database, Arch Intern Med, 165, 1756, 10.1001/archinte.165.15.1756 · DOI · Paper page
  3. Jevons, 1961, Celbenin-resistant staphylococci, BMJ, i, 124, 10.1136/bmj.1.5219.124-a · DOI · Paper page
  4. Enright, 2002, The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA), Proc Natl Acad Sci USA, 99, 7687, 10.1073/pnas.122108599 · DOI · Paper page
  5. Kluytmans-Vandenbergh, 2006, Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives, Clin Microbiol Infect, 12, 9, 10.1111/j.1469-0691.2006.01341.x · DOI · Paper page
  6. Appelbaum, 2006, The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, Clin Microbiol Infect, 12, 16, 10.1111/j.1469-0691.2006.01344.x · DOI · Paper page
  7. Deresinski, 2007, Counterpoint: vancomycin and Staphylococcus aureus—an antibiotic enters obsolescence, Clin Infect Dis, 44, 1543, 10.1086/518452 · DOI · Paper page
  8. Cosgrove, 2003, The impact of antimicrobial resistance on health and economic outcomes, Clin Infect Dis, 36, 1433, 10.1086/375081 · DOI · Paper page
  9. Katayama, 2000, A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus, Antimicrob Agents Chemother, 44, 1549, 10.1128/AAC.44.6.1549-1555.2000 · DOI · Paper page
  10. Ito, 2003, Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC, Drug Resist Updat, 6, 41, 10.1016/S1368-7646(03)00003-7 · DOI · Paper page
  11. Chambers, 1985, Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin, J Clin Invest, 76, 325, 10.1172/JCI111965 · DOI
  12. Ito, 2001, Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 45, 1323, 10.1128/AAC.45.5.1323-1336.2001 · DOI · Paper page
  13. Ma, 2002, Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains, Antimicrob Agents Chemother, 46, 1147, 10.1128/AAC.46.4.1147-1152.2002 · DOI · Paper page
  14. Okuma, 2002, Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community, J Clin Microbiol, 40, 4289, 10.1128/JCM.40.11.4289-4294.2002 · DOI · Paper page
  15. Ito, 2004, Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC, Antimicrob Agents Chemother, 48, 2637, 10.1128/AAC.48.7.2637-2651.2004 · DOI · Paper page
  16. Baba, 2002, Genome and virulence determinants of high virulence community-acquired MRSA, Lancet, 359, 1819, 10.1016/S0140-6736(02)08713-5 · DOI · Paper page
  17. Couto, 1996, Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri, Microb Drug Resist, 2, 377, 10.1089/mdr.1996.2.377 · DOI · Paper page
  18. Shorr, 2006, Healthcare-associated bloodstream infection: a distinct entity, Insights from a large U.S. database Crit Care Med, 34, 2588
  19. Siegman-Igra, 2002, Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia, Clin Infect Dis, 34, 1431, 10.1086/339809 · DOI · Paper page
  20. Drew, 2007, Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections, Pharmacotherapy, 27, 227, 10.1592/phco.27.2.227 · DOI
  21. 2004, Bad bugs, no drugs
  22. Powers, 2004, Antimicrobial drug development—the past, the present, and the future, Clin Microbiol Infect, 10, 23, 10.1111/j.1465-0691.2004.1007.x · DOI · Paper page
  23. Jones, 2002, In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci, J Antimicrob Chemother, 50, 915, 10.1093/jac/dkf249 · doi:10.1093/jac/dkf249
  24. Chopra, 2001, Glycylcyclines: Third generation tetracycline antibiotics, Curr Opin Pharmacol, 1, 464, 10.1016/S1471-4892(01)00081-9 · DOI
  25. Doan, 2006, Tigecycline: a glycylcycline antimicrobial agent, Clin Ther, 28, 1079, 10.1016/j.clinthera.2006.08.011 · DOI
  26. 2006, Tygacil. European Public Assessment Report
  27. Goldstein, 2006, In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections, Antimicrob Agents Chemother, 50, 2875, 10.1128/AAC.00286-06 · DOI
  28. Jones, 2005, Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol, J Chemother, 17, 593, 10.1179/joc.2005.17.6.593 · DOI
  29. Saravolatz, 2007, Comparative activity of telavancin against isolates of community-acquired methicillin-resistant Staphylococcus aureus, J Antimicrob Chemother, 2007, 406, 10.1093/jac/dkm211 · DOI
  30. 2007, Cubicin IV, Prescribing information
  31. Petersen, 2002, In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens, Antimicrob Agents Chemother, 46, 2595, 10.1128/AAC.46.8.2595-2601.2002 · DOI · Paper page
  32. 2006, Cubicin, European Public Assessment Report
  33. Lofland, 2004, In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698, J Antimicrob Chemother, 53, 664, 10.1093/jac/dkh129 · DOI
  34. Fritsche, 2005, Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance, Antimicrob Agents Chemother, 49, 1468, 10.1128/AAC.49.4.1468-1476.2005 · DOI
  35. Lowy, 2003, Antimicrobial resistance: the example of Staphylococcus aureus, J Clin Invest, 111, 1265, 10.1172/JCI200318535 · doi:10.1172/jci200318535 · Paper page
  36. Hartman, 1984, Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus, J Bacteriol, 158, 513, 10.1128/JB.158.2.513-516.1984 · DOI · Paper page
  37. Utsui, 1985, Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 28, 397, 10.1128/AAC.28.3.397 · DOI · Paper page
  38. Song, 1987, Evolution of an inducible penicillin-target protein in methicillin-resistant Staphylococcus aureus by gene fusion, FEBS Lett, 221, 167, 10.1016/0014-5793(87)80373-3 · DOI · Paper page
  39. de Jonge, 1993, Abnormal peptidoglycan produced in a methicillin-resistant strain of Staphylococcus aureus grown in the presence of methicillin: functional role for penicillin-binding protein 2A in cell wall synthesis, Antimicrob Agents Chemother, 37, 342, 10.1128/AAC.37.2.342 · DOI
  40. Pinho, 2001, An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci, Proc Natl Acad Sci USA, 98, 10886, 10.1073/pnas.191260798 · DOI · Paper page
  41. Berger-Bachi, 1994, Expression of resistance to methicillin, Trends Microbiol, 2, 389, 10.1016/0966-842X(94)90617-3 · DOI
  42. de Lencastre, 1994, Molecular aspects of methicillin resistance in Staphylococcus aureus, J Antimicrob Chemother, 33, 7, 10.1093/jac/33.1.7 · DOI
  43. Katayama, 2004, PBP 2a mutations producing very-high-level resistance to beta-lactams, Antimicrob Agents Chemother, 48, 453, 10.1128/AAC.48.2.453-459.2004 · doi:10.1128/aac.48.2.453-459.2004
  44. Moreillon, 1991, Beta-lactam antibiotics active against methicillin-resistant Staphylococcus aureus, J Infect Dis, 163, 1165, 10.1093/infdis/163.5.1165 · doi:10.1093/infdis/163.5.1165
  45. Franciolli, 1991, Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus, J Infect Dis, 163, 514, 10.1093/infdis/163.3.514 · DOI
  46. Hirano, 1991, Beta-lactam–beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci, Antimicrob Agents Chemother, 35, 685, 10.1128/AAC.35.4.685 · doi:10.1128/aac.35.4.685
  47. Chambers, 1995, In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a, Antimicrob Agents Chemother, 39, 462, 10.1128/AAC.39.2.462 · doi:10.1128/aac.39.2.462
  48. Que, 1998, The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus, J Infect Dis, 177, 146, 10.1086/513805 · doi:10.1086/513805
  49. Lim, 2002, Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus, Nat Struct Biol, 9, 870
  50. Tomasz, 2003, ‘Intelligence coup’ for drug designers: crystal structure of Staphylococcus aureus beta-lactam resistance protein PBP2A, Lancet, 361, 795, 10.1016/S0140-6736(03)12719-5 · DOI
  51. Guignard, 2005, Beta-lactams against methicillin-resistant Staphylococcus aureus, Curr Opin Pharmacol, 5, 479, 10.1016/j.coph.2005.06.002 · DOI
  52. Bush, 2007, Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy, Expert Opin Investig Drugs, 16, 419, 10.1517/13543784.16.4.419 · DOI
  53. Glinka, 2002, Novel cephalosporins for the treatment of MRSA infections, Curr Opin Investig Drugs, 3, 206
  54. Hebeisen, 2001, In vitro and in vivo properties of Ro 63–9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci, Antimicrob Agents Chemother, 45, 825, 10.1128/AAC.45.3.825-836.2001 · DOI · Paper page
  55. Deshpande, 2004, Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates, Diagn Microbiol Infect Dis, 50, 73, 10.1016/j.diagmicrobio.2004.04.011 · doi:10.1016/j.diagmicrobio.2004.04.011
  56. Zbinden, 2002, In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters, Antimicrob Agents Chemother, 46, 871, 10.1128/AAC.46.3.872-875.2002 · doi:10.1128/aac.46.3.872-875.2002
  57. Noel, 2008, Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria, Antimicrob Agents Chemother, 52, 37, 10.1128/AAC.00551-07 · DOI · Paper page
  58. Noel, 2008, A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections, Clin Infect Dis, 46, 647, 10.1086/526527 · DOI · Paper page
  59. Lipsky, 2004, Diagnosis and treatment of diabetic foot infections, Clin Infect Dis, 39, 885, 10.1086/424846 · DOI · Paper page

Cited by

See all 39

Metadata

Authors
Moreillon, P.
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2008-04
Volume
14
Pages
32-41
ISSN
1198-743X
Cited by
39
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New and emerging treatment of Staphylococcus aureus infections in the hospital setting. https://app.cochat.ai/papers/10.1111/j.1469-0691.2008.01961.x
The paper
Moreillon, P. (2008). New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clinical Microbiology and Infection. https://doi.org/10.1111/j.1469-0691.2008.01961.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.